Debiopharm S.A. Presents Phase I Monthly Implant And Phase II Daily Oral Results Of ZT-1 For Alzheimer’s Disease

Debiopharm S.A., the independent drug development company specialising in oncology and serious medical conditions, presented results of two ZT-1 studies at the 9th International Geneva Springfield Symposium on Advances in Alzheimer Therapy.